RVMDW / Revolution Medicines, Inc. - Equity Warrant - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Revenue Participation Right Purchase and Sale Agreement dated June 23, 2025, by and between Royalty Pharma Investments 2019 ICAV and the Company

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. Revenue Participation Right Purchase and Sale Agreement By and Between Revolution Medicines, Inc. and Royalty Pharma Investments 2019 ICAV Dated as of June 23, 2025 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commiss

Loan Agreement dated June 23, 2025, by and among Wilmington Trust, National Association, as trustee, Royalty Pharma Development Funding, LLC, and the Company

Exhibit 10.2 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AGREEMENT dated as of June 23, 2025 among REVOLUTION MEDICINES, INC. (as Borrower), WILMINGTON TRUST, NATIONAL ASSOCIATION (as Administrative Agent), and ROYALTY PHARMA DEVELOPMENT FUNDING, LLC (as a Lender)

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

Exhibit 99.1 Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress • Strong execution of two ongoing Phase 3 trials of daraxonrasib; for RASolute 302, company is winding down enrollment in U.S. and expects to complete enrollment of the trial this year • FDA Breakthrough Therapy Designations granted for two RAS(ON) inhibitors, daraxonrasib and elironras

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 REVOLUTION MEDICINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with

EX-99.1 Exhibit 99.1 Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers • Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt • Company m

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Revolution Medicine

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 REVOLUTION MEDICINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Exhibit 99.1 Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress • Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year • New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first

Non-Employee Director Compensation Program.

Exhibit 10.1 Revolution Medicines, Inc. Non-Employee Director Compensation Program As amended, March 27, 2025 This Revolution Medicines, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”). This Program shall become effective as of immediately prior to the the Company’s 2025 annual meeting of s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2025 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously tr

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 tria

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commi

Seventh Amendment, dated as of November 5, 2024, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc.

Exhibit 10.2I SEVENTH AMENDMENT TO LEASE This SEVENTH AMENDMENT TO LEASE (“Seventh Amendment”) is made and entered into as of November 5, 2024 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Tenant”). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated Ja

As filed with the Securities and Exchange Commission on February 26, 2025

As filed with the Securities and Exchange Commission on February 26, 2025 Registration No.

Sublease between Editco Bio Inc. and Revolution Medicines, Inc., dated as of November 5, 2024

Exhibit 10.2J SUBLEASE (Redwood City, California) THIS SUBLEASE (this “Sublease”) is entered into as of November 5, 2024 (the “Effective Date”), by and between REVOLUTION MEDICINES, INC., a Delaware corporation (“Sublandlord”), and EDITCO BIO INC., a Delaware corporation (“Subtenant”). Sublandlord and Subtenant may each be referred to herein as a “Party”, and collectively, the “Parties”. RECITALS

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.000

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Revolution Medicines, Inc. Name Jurisdiction of Incorporation or Organization Warp Drive Bio, Inc. Delaware EQRx, LLC Delaware EQRx UK Limited England and Wales EQRx International, Inc. Delaware Verum Norte Therapeutics, Inc. Delaware

Insider Trading Compliance Policy and Procedures

Exhibit 19.1 Revolution Medicines, Inc. Insider Trading Compliance Policy and Procedures Effective May 8, 2023 Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information regarding that company and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medi

Description of Securities.

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Revolution Medicines, Inc. (“we,” “us,” “our” and the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock and public warrants. The following description of our commo

Form of Pre-Funded Warrant

Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK   Number of Shares: [    ] (subject to adjustment) Warrant No.    Original Issue Date: December 5, 2024 Revolution Medicines, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder

Underwriting Agreement, dated as of December 3, 2024, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 Revolution Medicines, Inc. 14,130,436 Shares of Common Stock and Pre-Funded Warrants to Purchase 2,173,917 Shares of Common Stock Underwriting Agreement December 3, 2024 J.P. MORGAN SECURITIES LLC TD SECURITIES (USA) LLC GOLDMAN SACHS & CO. LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madiso

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277640 Prospectus supplement (To the Prospectus dated March 4, 2024) 14,130,436 Shares of Common Stock Pre-funded Warrants to Purchase 2,173,917 Shares of Common Stock Revolution Medicines, Inc. is offering 14,130,436 shares of its common stock and, in lieu of offering shares of its common stock to certain investors, pre-funde

Calculation of Filing Fee Tables (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revolution Medicines, Inc.

Issuer Free Writing Prospectus

FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated December 3, 2024 Relating to Preliminary Prospectus Supplement Dated December 2, 2024 Registration Statement No.

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

424B5 1 d869047d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277640 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Revolution Medicines, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-

RVMD / Revolution Medicines, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Employment Agreement, dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Jack Anders.

Exhibit 10.2 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Jack Anders (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employment Agree

Sixth Amendment, dated as of July 12, 2024, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc.

Exhibit 10.1 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (“Sixth Amendment”) is made and entered into as of July 12, 2024 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Tenant”). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated January 15,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commi

REVOLUTION MEDICINES, INC. $500,000,000 SALES AGREEMENT

Exhibit 1.1 REVOLUTION MEDICINES, INC. $500,000,000 SALES AGREEMENT August 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: Revolution Medicines, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinica

Exhibit 99.1 Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antit

Employment Agreement dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Xiaolin Wang, Sc.D.

Exhibit 10.3 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Xiaolin Wang, Sc.D. (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employme

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 REVOLUTION MEDIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Sales Agreement, dated as of August 7, 2024, by and between Revolution Medicines, Inc. and TD Securities (USA), LLC.

Exhibit 1.1 REVOLUTION MEDICINES, INC. $500,000,000 SALES AGREEMENT August 7, 2024 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: Revolution Medicines, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time

Employment Agreement dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Xiaolin Wang, Sc.D.

Exhibit 10.3 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Xiaolin Wang, Sc.D. (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employme

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commiss

Calculation of Filing Fee Tables Form S-3 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Revolution Medicines, Inc.

Sixth Amendment, dated as of July 12, 2024, to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc.

Exhibit 10.1 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (“Sixth Amendment”) is made and entered into as of July 12, 2024 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and REVOLUTION MEDICINES, INC., a Delaware corporation (“Tenant”). r e c i t a l s : A. Landlord and Tenant are parties to the Lease dated January 15,

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time

Exhibit 99.1 Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., August 7, 2024 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Employment Agreement, dated as of August 1, 2024 by and between Revolution Medicines, Inc. and Jack Anders

Exhibit 10.2 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), entered into effective as of August 1, 2024 (the “Effective Date”), is between Revolution Medicines, Inc., a Delaware corporation (the “Company”) and Jack Anders (“Executive” and, together with the Company, the “Parties”). This Agreement supersedes in its entirety that certain Employment Agree

Up to $500,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-277640 PROSPECTUS SUPPLEMENT (To prospectus dated March 4, 2024) Up to $500,000,000 Common Stock We have entered into a sales agreement with TD Securities (USA) LLC (“TD Cowen”) relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sale

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 REVOLUTION MEDICINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table.

EXHIBIT 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 3— Combined Prospectuses Security Type Security Class Title Amount of Securities Previously Registered Maximum Aggregate Offering Price of Securities Previously Registered Form Type File Number Initial Effective Date Equity Common Stock Underly

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2024 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commission

Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time

Exhibit 99.1 Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2024 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its

As filed with the Securities and Exchange Commission on May 8, 2024

Table of Contents As filed with the Securities and Exchange Commission on May 8, 2024 Registration No.

Non-Employee Director Compensation Program

Exhibit 10.1 Revolution Medicines, Inc. Non-Employee Director Compensation Program As amended, March 21, 2024 This Revolution Medicines, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”). This Program shall become effective as of immediately prior to the the Company’s 2024 annual meeting of s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant☒ Filed by a party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant☒ Filed by a party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-

140 Scott Drive

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh April 19, 2024 Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul VIA EDGAR Hamburg Silicon Valley Hong Kong Singapore United States Securities and Exchange Commissions H

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Revolution Medicines, Inc.

Form of Indenture.

Exhibit 4.6 REVOLUTION MEDICINES, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5    Section 2.2. Est

Amendment No. 1 to Sales Agreement, dated March 4, 2024, by and between Revolution Medicines, Inc. and Cowen and Company, LLC.

Exhibit 1.2B AMENDMENT NO. 1 TO THE SALES AGREEMENT March 4, 2024 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by Revolution Medicines, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“TD Cowen”), that are parties

Unaudited pro forma condensed combined financial information of Revolution Medicines, Inc. and EQRx, Inc. for the year ended December 31, 2023.

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is prepared in accordance with the regulations of the U.S. Securities and Exchange Commission (“SEC”) and give effect to the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”) by Revolution Medicines, Inc., a Delaware corp

As filed with the Securities and Exchange Commission on March 4, 2024

Table of Contents As filed with the Securities and Exchange Commission on March 4, 2024 Registration No.

Exhibit 4.3

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Revolution Medicines, Inc. (“we,” “us,” “our” and the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock and public warrants. The following description of our commo

Warrant Agreement, dated April 6, 2021, by and between Continental Stock Transfer & Trust Company and EQRx, Inc.

Exhibit 4.4 (a) WARRANT AGREEMENT CM LIFE SCIENCES III INC. and CONTINENTAL STOCK TRANSFER & TRUST COMPANY Dated April 6, 2021 THIS WARRANT AGREEMENT (this “Agreement”), dated April 6, 2021, is by and between CM Life Sciences III Inc., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (in such capacity, the “Warrant Age

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.000

As filed with the Securities and Exchange Commission on February 26, 2024

As filed with the Securities and Exchange Commission on February 26, 2024 Registration No.

Subsidiaries of Registrant.

Exhibit 21.1 List of Subsidiaries of Revolution Medicines, Inc. Name Jurisdiction of Incorporation or Organization Warp Drive Bio, Inc. Delaware EQRx, LLC Delaware EQRx UK Limited England and Wales EQRx International, Inc. Delaware Verum Norte Therapeutics, Inc. Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commi

Policy for Recovery of Erroneously Awarded Compensation

Exhibit 97 REVOLUTION MEDICINES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Revolution Medicines, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of November 17, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11 of this Policy. 1.

Agreement and Plan of Merger, dated August 5, 2021, by and among EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

Exhibit 4.5 Composite Agreement and Plan of Merger Agreement and Plan of Merger, dated as of August 5, 2021, as amended September 21, 2021 and October 28, 2021, by and among CM Life Sciences III, Inc., Clover III Merger Sub, Inc., and EQRx, Inc. (composite copy incorporating the Agreement and Plan of Merger, dated as of August 5, 2021, Amendment to Agreement and Plan of Merger, dated as of Septemb

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., February 26, 2024 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medi

RVMD / Revolution Medicines, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Numb

RVMD / Revolution Medicines, Inc. / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

RVMD / Revolution Medicines, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A 1 d771197dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Ch

RVMD / Revolution Medicines, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01819-revolutionmedicinesi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: REVOLUTION Medicines Inc Title of Class of Securities: Common Stock CUSIP Number: 76155X100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

Joint Filing Statement

EX-99.A 2 d771197dex99a.htm EX-99.A Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned. BB Biotech AG Date: February 6, 2024 By: /s/ Martin Gubler Signatory Authority Name: Martin Gubler Title: Signatory Authority Date: February 6, 2024 By: /s/ Ivo Betscha

RVMD / Revolution Medicines, Inc. / Farallon Capital Partners, L.P. Passive Investment

SC 13G/A 1 rvmd13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) * Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appro

RVMD / Revolution Medicines, Inc. / COLUMN GROUP III, LP - SC 13G/A Passive Investment

SC 13G/A 1 d747658dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement)

RVMD / Revolution Medicines, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements

Exhibit 99.1 On Target to Outsmart Cancer January 9, 2024 © 2024 Revolution Medicines, Inc. 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 REVOLUTION MEDICI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commiss

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is prepared in accordance with the regulations of the U.S. Securities and Exchange Commission (“SEC”) and give effect to the previously announced acquisition of EQRx, Inc., a Delaware corporation (“EQRx”) by Revolution Medicines, Inc., a Delaware corp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 (November 8,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 (November 8, 2023) Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of

United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 REVOLUTION MEDICINES, INC. (Exact name of regis

United States Securities and Exchange Commission Washington, D.C. 20549 Form 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Numbe

Appointment, Assignment and Assumption Agreement, dated November 9, 2023, by and among EQRx, Inc., Revolution Medicines, Inc., Continental Stock Transfer & Trust Company and Equiniti Trust Company, LLC.

Exhibit 4.2(b) APPOINTMENT, ASSIGNMENT AND ASSUMPTION AGREEMENT THIS APPOINTMENT, ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is entered into and effective as of November 9, 2023 by and among EQRx, Inc., a Delaware corporation (the “Company”), Revolution Medicines, Inc. (“Parent”), Continental Stock Transfer & Trust Company, a New York corporation (“Continental”) and Equiniti Trust Comp

RVMD / Revolution Medicines Inc / Farallon Capital Partners, L.P. Passive Investment

SC 13G 1 rvmd13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (Cusip Number) October 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

RVMD / Revolution Medicines Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commi

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO

Exhibit 99.1 Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress Promising clinical data for RMC-6236, a RASMULTI(ON) Inhibitor, and RMC-6291, a RASG12C(ON) Inhibitor, presented at AACR-NCI-EORTC (“Triple”) and ESMO Meetings Acquisition of EQRx, Inc. expected to close later this month Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Tim

Fifth Amendment to Lease and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of August 3, 2023

Exhibit 10.3 1505-100G; 1509-100; 1510-100A; 1511-100B Revolution Medicines, Inc. 5th Amendment FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of August 3, 2023 (the “Fifth Amendment Effective Date”), by and between HCP LS Redwood City, LLC, a Delaware limited partnership (“Landlord”) and Revolution Medicines, Inc., a Delaware corporation (“Tenant”). REC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Regulation FD Disclosure, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112

EXHIBIT 99.1 Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. Revolution Medicines Also Announces the Final Exchange Ratio of 0.1112 REDWOOD CITY, Calif., November 1, 2023 – Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant  ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 Revolution Medic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements

Exhibit 99.1 On Target to Outsmart Cancer October 22, 2023 © 2023 Revolution Medicines 2 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial posit

###

Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: October 23, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc., a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2023 REVOLUTION MEDIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

MERGER AND SHARE ISSUANCE PROPOSALS—YOUR VOTE IS VERY IMPORTANT

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-274499 MERGER AND SHARE ISSUANCE PROPOSALS—YOUR VOTE IS VERY IMPORTANT Dear Stockholders: On July 31, 2023, Revolution Medicines, Inc., which is referred to as Revolution Medicines, EQRx, Inc., which is referred to as EQRx, Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines, which is referred t

Form of Proxy Card for Special Meeting of Revolution Medicines, Inc.

Exhibit 99.3 REVOLUTION MEDICINES, INC. 700 SAGINAW DR. REDWOOD CITY, CA 94063 SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET www.proxyvote.com or scan the QR Barcode above Before The Meeting - Go to Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time the day before the cut-off date or meeting date. Have your proxy card

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Revolution Medicines, Inc.

Consent of MTS Securities, LLC.

Exhibit 99.1 CONSENT OF MTS SECURITIES, LLC We hereby consent to (i) the inclusion of our opinion letter, dated July 31, 2023, addressed to the Board of Directors of EQRx, Inc. (“EQRx”) as Annex B to the joint proxy statement/prospectus that forms a part of the Amendment No. 1 to the Registration Statement on Form S-4 of Revolution Medicines, Inc. (“Revolution Medicines”) relating to the proposed

Form of Proxy Card for Special Meeting of EQRx, Inc.

Exhibit 99.4 SCAN TO VIEW MATERIALS & VOTE EQRX, INC. 50 HAMPSHIRE STREET CAMBRIDGE, MA 02139 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on November 7, 2023. Have your proxy card in hand when you access the web site and fo

As filed with the U.S. Securities and Exchange Commission on September 27, 2023

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 27, 2023 Registration No. 333-274499 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 47-2029180 (State or o

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 September 27, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Re: Revolution Medicines, Inc. Registration Statement on Form S-4 File No. 333-274499 Request for Acceleration of Effectiveness To the addressee set forth above: In ac

Consent of Sandra J. Horning, M.D. to be named as a director.

Exhibit 99.2 CONSENT OF SANDRA J. HORNING, M.D. In connection with the filing by Revolution Medicines, Inc. (the “Company”) of its Registration Statement (the “Registration Statement”) on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Revolution Medicines, Inc.

Consent of MTS Securities, LLC.

Exhibit 99.1 CONSENT OF MTS SECURITIES, LLC We hereby consent to (i) the inclusion of our opinion letter, dated July 31, 2023, addressed to the Board of Directors of EQRx, Inc. (“EQRx”) as Annex B to the joint proxy statement/prospectus that forms a part of the Registration Statement on Form S-4 of Revolution Medicines, Inc. (“Revolution Medicines”) relating to the proposed mergers of (a) Equinox

As filed with the U.S. Securities and Exchange Commission on September 13, 2023

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 47-2029180 (State or other jurisdiction of inco

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Company to provide clinical updates for RMC-6236 at Triple (AACR-NCI-EORTC) Meeting and ESMO (European Society for Medical Oncology) Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and the first combination study of RMC-6236 and RMC-6291 Announced acquisition of EQRx, Inc.

Filed by Revolution Medicines, Inc.

Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: August 1, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc., a De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 REVOLUTION MEDICINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Filed by Revolution Medicines, Inc.

425 Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: August 1, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc.,

Agreement and Plan of Merger, dated July 31, 2023, by and among Revolution Medicines, Inc., EQRx, Inc., Equinox Merger Sub I, Inc. and Equinox Merger Sub II LLC.

EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among REVOLUTION MEDICINES, INC., a Delaware corporation, EQRX, INC., a Delaware corporation, EQUINOX MERGER SUB I, INC., a Delaware corporation and EQUINOX MERGER SUB II LLC, a Delaware limited liability company Dated as of July 31, 2023 TABLE OF CONTENTS Page Article 1 Description of Transaction 2 Section 1.1 The Mergers 2 Section 1.2 Effects of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 REVOLUTION MEDICINE

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commi

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fort

425 Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: August 1, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc.,

Form of Voting Agreement with Revolution Medicines, Inc.

EX-10.1 Exhibit 10.1 FORM OF COMPANY STOCKHOLDER VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of July 31, 2023 (the “Agreement Date”), by and among Revolution Medicines, Inc., a Delaware corporation (“Parent”), and the undersigned, a stockholder of EQRx, Inc., a Delaware corporation (the “Company”, and such stockholder, the “Stockholder”). Parent and the St

Filed by Revolution Medicines, Inc.

Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: August 1, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc., a De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 EQRX, INC. (Exact n

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 EQRX, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40312 86-1691173 (State or Other Jurisdiction of Incorporation) (Commission File Number) (

Form of Lock-up Agreement with Revolution Medicines, Inc.

EX-10.2 Exhibit 10.2 FORM OF STOCKHOLDER LOCK-UP AGREEMENT July 31, 2023 Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 To the addressee set forth above: The undersigned understands that, on the date hereof, Revolution Medicines, Inc., a Delaware corporation (“Parent”), Equinox Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger

FORM OF PARENT STOCKHOLDER VOTING AGREEMENT

EX-99.1 Exhibit 99.1 FORM OF PARENT STOCKHOLDER VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of July 31, 2023 (the “Agreement Date”), by and among EQRx, Inc., a Delaware corporation (the “Company”), and the undersigned, a stockholder of Revolution Medicines, Inc., a Delaware corporation (“Parent”, and such stockholder, the “Stockholder”). The Company and th

###

Filed by Revolution Medicines, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934 Subject Company: EQRx, Inc. Commission File No.: 001-40312 Date: August 1, 2023 This filing relates to the proposed transaction between Revolution Medicines, Inc. a Delaware corporation (“Revolution Medicines”), and EQRx, Inc., a De

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fort

EX-99.2 Exhibit 99.2 Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital Revolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet Agreement is the Result of a Rigorous Process Conducted by Independent Transaction Committee of EQRx Board to

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 30, 2023 with respect to the shares of Common Stock, $0.0001 par value per share of Revolution Medicines, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in acc

RVMD / Revolution Medicines Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Numbe

RVMD / Revolution Medicines Inc / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 rvmd13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) June 7, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 REVOLUTION MEDICINES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission

Fourth Amendment to Lease and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of March 24, 2023

Exhibit 10.2 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE ("Fourth Amendment") is made and entered into as of March 24, 2023 (the “Effective Date”), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership ("Landlord"), and REVOLUTION MEDICINES, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A. Landlord and Tenant are parties to the Lease dated January 15, 20

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commission

Non-Employee Director Compensation Program

Exhibit 10.1 Revolution Medicines, Inc. Non-Employee Director Compensation Program As amended, March 23, 2023 This Revolution Medicines, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2020 Incentive Award Plan (the “Plan”). This Program shall become effective as of immediately prior to the the Company’s 2023 annual meeting of s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment o

Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress First Wave of Investigational RAS(ON) Inhibitors – RMC-6236 (RASMULTI), RMC-6291 (KRASG12C) and RMC-9805 (KRASG12D) – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commercial planning $909.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14( a ) of th e Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14( a ) of th e Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

Underwriting Agreement, dated as of March 2, 2023, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, Cowen and Company, LLC, SVB Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.

EX-1.1 Exhibit 1.1 Revolution Medicines, Inc. 13,636,364 Shares of Common Stock Underwriting Agreement March 2, 2023 J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC SVB SECURITIES LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexington Av

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 REVOLUTION MEDICINE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253790 Prospectus supplement (To the Prospectus dated March 2, 2021) 13,636,364 shares Common stock Revolution Medicines, Inc. is offering 13,636,364 shares of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.” The last reported sale price of our common stock on the N

Calculation of Filing Fee Tables (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Car

Exhibit Filing Fees Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revolution Medicines, Inc.

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

424B5 1 d459660d424b5.htm 424B5 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Filed Pursuant to Rule 424(b)

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASM

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805 (KRASG12D) expected to begin clinical development in mid-2023 Growing pipeline of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medi

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 As filed with the Securities and Exchange Commission on February 27, 2023 Registration No.

Filing Fee Table.

EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo

RVMD / Revolution Medicines Inc / BB BIOTECH AG - SC 13G/A Passive Investment

SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to des

POWER OF ATTORNEY

EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Undersigned personally present.

RVMD / Revolution Medicines Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 d441994dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Revolution Medicines, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement)

JOINT FILING AGREEMENT

EX-99.1 2 d422395dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that

RVMD / Revolution Medicines Inc / COLUMN GROUP III, LP - SC 13G/A Passive Investment

SC 13G/A 1 d422395dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement)

RVMD / Revolution Medicines Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: REVOLUTION Medicines Inc. Title of Class of Securities: Common Stock CUSIP Number: 76155X100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

RVMD / Revolution Medicines Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

RVMD / Revolution Medicines Inc / EcoR1 Capital, LLC Passive Investment

SC 13G 1 rvmd20230120.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) January 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appr

On Target to Outsmart Cancer TM January 10, 2023

On Target to Outsmart Cancer TM January 10, 2023 Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Revolution Medicines, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39219 47-2029180 (State or Other Jurisdiction of Incorporation) (Commis

RVMD / Revolution Medicines Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) November 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inh

Exhibit 99.1 Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to support advancement of pipeline Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Ca

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

RVMD / Revolution Medicines Inc / BB BIOTECH AG - SC 13G Passive Investment

SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) September 22, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule purs

Joint Filing Statement

Exhibit A Joint Filing Statement We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissi

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targete

Exhibit 99.1 Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress First two RAS(ON) Inhibitor drug candidates advance into clinical development Successful equity financing supports development of portfolio of targeted drug candidates for RAS-addicted cancers Appointment of industry experts in commercial oncology and financial strategy to Board of Dire

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Underwriting Agreement, dated as of July 19, 2022, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.

EX-1.1 2 d61456dex11.htm EX-1.1 Exhibit 1.1 Revolution Medicines, Inc. 11,500,000 Shares of Common Stock Underwriting Agreement July 19, 2022 J.P. MORGAN SECURITIES LLC COWEN AND COMPANY, LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Cowen and Company, LLC 599 Lexing

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2022 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Calculation of Filing Fee Tables (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities

EX-FILING FEES 2 d332737dexfilingfees.htm EX-FILING FEES Exhibit Filing Fees Calculation of Filing Fee Tables 424(b)(5) (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Pri

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253790 Prospectus supplement (To the Prospectus dated March 2, 2021) 11,500,000 shares Common stock Revolution Medicines, Inc. is offering 11,500,000 shares of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?RVMD.? The last reported sale price of our common stock on the Nasdaq

Revolution Medicines, Inc. 700 Saginaw Drive Redwood City, California 94063 (650) 481-6801 Attention: Investor Relations

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253790 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2022 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission

RVMD / Revolution Medicines Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76155X100 (CUSIP Number) June 16, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission

First Amendment to Employment Agreement dated June 10, 2022 by and between Revolution Medicines, Inc. and Mark Goldsmith, M.D., Ph.D.

Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this ?Amendment?) is entered into as of June 10, 2022, by and between Revolution Medicines, Inc. (the ?Company?) and Mark Goldsmith, M.D., Ph.D. (?Executive? and together with the Company, the ?Parties?). RECITALS: WHEREAS, the Parties entered into that certain employment agreement (the ?Agreement?)

Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Comp

Exhibit 99.1 Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination with Lumakras? (sotorasib) in patients with advanced non-small cell lung cancer continues

Employment Agreement by and between Revolution Medicines, Inc.

Exhibit 10.2 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into effective as of April 29, 2022 (the ?Effective Date?), is between Revolution Medicines, Inc., a Delaware corporation (the ?Company?) and Jack Anders (?Executive? and, together with the Company, the ?Parties?). This Agreement supersedes in its entirety that certain offer letter bet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Non-Employee Director Compensation Program

Exhibit 10.1 Revolution Medicines, Inc. Non-Employee Director Compensation Program As amended, March 10, 2022 This Revolution Medicines, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2020 Incentive Award Plan (the ?Plan?). The cash and equity compensation described in this Program shall be paid or made, as applicable, automati

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission

Employment Agreement by and between Revolution Medicines, Inc. and Xiaolin Wang Sc.D

Exhibit 10.3 REVOLUTION MEDICINES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), entered into effective as of April 28, 2022 (the ?Effective Date?), is between Revolution Medicines, Inc., a Delaware corporation (the ?Company?) and Xiaolin Wang, Sc.D. (?Executive? and, together with the Company, the ?Parties?). This Agreement supersedes in its entirety that certain offer le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Rece

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in Global Phase 2 Study Evaluating Combination of RMC-4630 and Lumakras? (sotorasib

Description of Common Stock.

Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Revolution Medicines, Inc. (?we,? ?us,? ?our? and the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock. The following description of our common stock is a summary a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medi

Filing Fee Table.

EX-FILING FEES 4 d273100dexfilingfees.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Ra

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commi

As filed with the Securities and Exchange Commission on February 28, 2022

S-8 1 d273100ds8.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Revolution Medicines, Inc. (Exact name of Registrant as specified in its charter) Delaware 47-2029180 (State or other jurisdiction of incorpor

RVMD / Revolution Medicines Inc / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Numb

RVMD / Revolution Medicines Inc / Cormorant Asset Management, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

POWER OF ATTORNEY

EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec

Joint Filing Agreement

EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be

RVMD / Revolution Medicines Inc / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Revolution Medicines, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

RVMD / Revolution Medicines Inc / COLUMN GROUP III, LP - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

RVMD / Revolution Medicines Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: REVOLUTION Medicines Inc. Title of Class of Securities: Common Stock CUSIP Number: 76155X100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

RVMD / Revolution Medicines Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th

On Target to Outsmart CancerTM

Exhibit 99.1 On Target to Outsmart CancerTM Legal Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Calculation of Registration Fee Title of each class of securities to be registered Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, $0.0001 par value per share $250,000,000 $ 23,175

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-253790 Calculation of Registration Fee Title of each class of securities to be registered Proposed maximum aggregate offering price(1) Amount of registration fee(2) Common Stock, $0.0001 par value per share $250,000,000 $ 23,175 (1) The proposed maximum aggregate offering price is being used to calculate the registration fee p

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Third Amendment to Lease by and between HCP LS Redwood City, LLC and Revolution Medicines, Inc., dated as of November 1, 2021.

Exhibit 10.1 THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE ("Third Amendment") is made and entered into as of November 1, 2021 (the ?Effective Date?), by and between HCP LS REDWOOD CITY, LLC, a Delaware limited partnership ("Landlord"), and REVOLUTION MEDICINES, INC., a Delaware corporation ("Tenant"). R E C I T A L S : A.Landlord and Tenant are parties to the Lease dated January 15, 2015

Sales Agreement, dated November 10, 2011, by and between Revolution Medicines, Inc. and Cowen and Company, LLC.

Exhibit 1.1 EXECUTION VERSION REVOLUTION MEDICINES, INC. $250,000,000 SALES AGREEMENT November 10, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Revolution Medicines, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supportin

Exhibit 99.1 Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company Poised to Select Additional RAS(ON) Development Candidate in 2021; Mutant-Selective Inhibitors of

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commis

Non-Employee Director Compensation Program.

Exhibit 10.1 Revolution Medicines, Inc. Non-Employee Director Compensation Program As amended, June 22, 2021 This Revolution Medicines, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2020 Incentive Award Plan (the ?Plan?). The cash and equity compensation described in this Program shall be paid or made, as applicable, automatic

Letter Agreement and Amendment, dated as of August 5, 2021 by and between Revolution Medicines, Inc. and Genzyme Corporation.

Exhibit 10.2 EXECUTION VERSION [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. August 5, 2021 Revolution Medicines, Inc. 700 Saginaw Dr. Redwood City, CA 94063 To Whom It May Concern: Reference is hereby made to that ce

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the C

Exhibit 99.1 Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study Support Deprioritizing Certain Approaches and Focusing on Combinations of RMC-4630 with Direct

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commiss

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2021 REVOLUTION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) May 18, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated May 17, 2021 with respect to the shares of Common Stock, $0.0001 par value per share of Revolution Medicines, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in acco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Numbe

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39219 Revolution Medicines, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commission

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Featur

Exhibit 99.1 Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors; Scientific Publication is First to Demonstrate Anti-Drug Resistance Features Continued Advancement and Enrollment of Multiple RMC-4630 RAS Companion Inhibitor Combination Studies; Initiated Clinical Evaluation o

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissi

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

- DEF 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Amended and Restated Bylaws.

Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF REVOLUTION MEDICINES, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Revolution Medicines, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39219 47-2029180 (State or other jurisdiction of incorporation) (Commissio

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of R

Exhibit 99.1 Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to Support Targeted Combination Therapies Strengthened Balance Sheet ? Completed Financing Raising $281 Million i

- S-3ASR

Table of Contents As filed with the Securities and Exchange Commission on March 2, 2021 Registration No.

Form of Indenture.

Exhibit 4.4 REVOLUTION MEDICINES, INC. INDENTURE Dated as of , 20 [ ], as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. E

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39219 Revolution Medi

- S-8

As filed with the Securities and Exchange Commission on March 2, 2021 Registration No.

JOINT FILING AGREEMENT

EX-99.1 2 d122184dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* REVOLUTION MEDICINES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Revolution Medicines, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securitie

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Revolution Medicines, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Revolution Medicines, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Revolution Medicines, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 76155X100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) (CUSIP Number) F

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Revolution Medicines, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 76155X100 (CUSIP Number) February 13, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to